Is CRISPR Therapeutics Really Headed to $110?

Eric Volkman, The Motley Fool
·2-min read
Is CRISPR Therapeutics Really Headed to $110?
Is CRISPR Therapeutics Really Headed to $110?

One analyst goes contrarian, raising her price target on the stock following some very dispiriting news from the company.